EVALUATION DE LA RÉPONSE TUMORALE EN CANCÉROLOGIE DIGESTIVE

C A F C I M – 1 5 D É C E M B R E 2 0 1 2
EVALUATION DE LA RÉPONSE
TUMORALE EN CANCÉROLOGIE
DIGESTIVE
Dr David Higué
Centre hospitalier de la côte basque
Bayonne

PLAN
•Recist 1.1
•mRecist et CHC
•Réponse à l’imatinib dans les GIST
•Réponse au bévacizumab dans le CCR

A
European Journal of Cancer
Volume 45, Issue 2, January 2009, Pages 228-247
Response assessment in solid tumours (RECIST): Version 1.1 and supporting papers
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E.A. Eisenhauera, , , P. Therasseb, J. Bogaertsc, L.H. Schwartzd, D. Sargente, R. Fordf,
J. Danceyg, S. Arbuckh, S. Gwytheri, M. Mooneyg, L. Rubinsteing, L. Shankarg, L. Doddg,
R. Kaplanj, D. Lacombec, J. Verweijk
a
National Cancer Institute of Canada – Clinical Trials Group, 10 Stuart Street, Queen’s University,
Kingston, ON, Canada
b
GlaxoSmithKline Biologicals, Rixensart, Belgium
c
European Organisation for Research and Treatment of Cancer, Data Centre, Brussels, Belgium
d
Memorial Sloan Kettering Cancer Center, New York, NY, USA
e
Mayo Clinic, Rochester, MN, USA
f
RadPharm, Princeton, NJ,
USA
g
Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA
h
Schering-Plough, Kenilworth, NJ, USA
i
East Surrey Hospital, Redhill, Surrey, UK
j
National Cancer Research Network, Leeds, UK
k
Erasmus University Medical Center, Rotterdam, The Netherlands
Received 17 October 2008; Accepted 29 October 2008.
RECIST1.1
6500 patients!
18 000 lésions!

Calcul
RÈGLES DU CALCUL
•Jusqu’à 5
lésions en tout
•Jusqu’à 2
lésions par
organe
•Lésions supra
centimétriques / ADP
> 15mm
•Distance max
(adénopathies: petit
axe)
Nombre de lésions Choix des lésions
Axes mesurés

RÉSULTATS
•Réponse complète (RC): disparition de l’ensemble
des lésions
•Réponse partielle (RP): diminution ≥ 30%
•Maladie stable (MS): entre -30 et +20%
•Progression (P): augmentation ≥ 20% (et/ou
nouvelle lésion)